Thymosin alpha 1 for use in treatment of cystic fibrosis
AssigneeSciclone Pharmaceuticals International (Sg) Pte. Ltd.
InventorsLuigina Romani, Enrico Garaci
Life of this patent
Estimating the term…
Abstract
The present invention concerns Thymosin alpha 1 (Tα1) for use in treatment of cystic fibrosis as a CFTR corrector, CFTR potentiator and anti-inflammatory agent.
Claims12
A method of down-regulating inflammatory cytokines or regulating Th cell balance attributed to cystic fibrosis (CF) in a CF patient, comprising administering to the patient in need thereof a pharmaceutical composition comprising Thymosin alpha 1, wherein the method (i) down-regulates an inflammatory cytokine selected from the group consisting of IL-1α and IL-1β or (ii) promotes the Th1/Treg tolerogenic axis and restrains the inflammatory Th17/Th2 axis.
Dependencies are inferred from the claim text.